PL1858920T3 - Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą - Google Patents

Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą

Info

Publication number
PL1858920T3
PL1858920T3 PL06748228.1T PL06748228T PL1858920T3 PL 1858920 T3 PL1858920 T3 PL 1858920T3 PL 06748228 T PL06748228 T PL 06748228T PL 1858920 T3 PL1858920 T3 PL 1858920T3
Authority
PL
Poland
Prior art keywords
meningitis
sepsis
proteins
nucleic acids
escherichia coli
Prior art date
Application number
PL06748228.1T
Other languages
English (en)
Polish (pl)
Inventor
Mariagrazia Pizza
Laura Serino
Vega Masignani
Herve Tettelin
Scorza Francesco Berlanda
Moriel Danilo Gomes
Nathalie Norais
Maria Rita Fontana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1858920T3 publication Critical patent/PL1858920T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06748228.1T 2005-02-18 2006-02-17 Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą PL1858920T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65463205P 2005-02-18 2005-02-18
US71272005P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
PL1858920T3 true PL1858920T3 (pl) 2016-12-30

Family

ID=36917149

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06748228.1T PL1858920T3 (pl) 2005-02-18 2006-02-17 Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą
PL11150423T PL2351772T3 (pl) 2005-02-18 2006-02-17 Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11150423T PL2351772T3 (pl) 2005-02-18 2006-02-17 Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą

Country Status (18)

Country Link
US (4) US8758764B2 (enExample)
EP (2) EP1858920B1 (enExample)
JP (2) JP2008529558A (enExample)
AU (1) AU2006214064B2 (enExample)
CA (1) CA2601924A1 (enExample)
CY (2) CY1117732T1 (enExample)
DK (2) DK1858920T3 (enExample)
ES (2) ES2569654T3 (enExample)
HU (2) HUE027400T2 (enExample)
IL (2) IL185359A0 (enExample)
LT (1) LT2351772T (enExample)
MX (1) MX306302B (enExample)
NZ (3) NZ561042A (enExample)
PL (2) PL1858920T3 (enExample)
PT (1) PT2351772T (enExample)
SG (1) SG160329A1 (enExample)
SI (2) SI2351772T1 (enExample)
WO (1) WO2006089264A2 (enExample)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228454T3 (es) * 1999-02-26 2005-04-16 Chiron S.R.L. Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
ES2330083T3 (es) * 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
DK1858920T3 (en) 2005-02-18 2016-02-29 Glaxosmithkline Biolog Sa PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
WO2007000341A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
ITMI20081249A1 (it) * 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
JP5332237B2 (ja) * 2008-03-06 2013-11-06 味の素株式会社 Ｌ−システイン生産菌及びｌ−システインの製造法
AU2009294318B2 (en) 2008-09-18 2014-04-24 Novartis Ag Vaccine adjuvant combinations
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010124085A2 (en) * 2009-04-23 2010-10-28 Cornell University Compositions and methods for preventing and treating uterine disease
US9119802B2 (en) * 2009-05-06 2015-09-01 Cornell University E. coli LpfA antigen for prevention and treatment of infectious diseases
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
PT2464658E (pt) 2009-07-16 2015-01-14 Novartis Ag Imunogénios de escherichia coli desintoxicados
EP2277989A1 (en) 2009-07-24 2011-01-26 Technische Universiteit Delft Fermentative glycerol-free ethanol production
CN102740882A (zh) * 2009-08-27 2012-10-17 诺华有限公司 含有铝、寡核苷酸和聚阳离子的佐剂
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
ATE557035T1 (de) * 2009-09-10 2012-05-15 Univ Berlin Freie Identifizierung und charakterisierung eines neuartigen aviären pathogenen e. coli (apec) fimbrien-adhäsins
DK2482836T3 (en) * 2009-10-02 2016-06-06 Univ Oslo Hf Antibacterial polypeptides and the use thereof
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
WO2011069951A1 (en) 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
EP2590626B1 (en) 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
EP3243526B1 (en) 2010-07-06 2019-11-27 GlaxoSmithKline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
HRP20161352T1 (hr) 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
PL4066857T3 (pl) 2010-08-31 2023-03-20 Glaxosmithkline Biologicals Sa Pegylowane liposomy do dostarczania rna kodującego immunogen
CA2809863A1 (en) 2010-08-31 2012-03-08 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
CN103764121A (zh) 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
TR201900264T4 (tr) 2011-08-31 2019-02-21 Glaxosmithkline Biologicals Sa İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar.
EP2755994A2 (en) 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
KR101359844B1 (ko) * 2012-01-06 2014-02-25 씨제이제일제당 (주) 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법
EP2806026B1 (en) * 2012-01-18 2018-12-26 Mitsui Chemicals, Inc. Method for producing 1,5-pentamethylenediamine, mutant lysine decarboxylase, method for producing 1,5-pentamethylene diisocyanate and method for producing polyisocyanate composition
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CA2865759C (en) 2012-03-07 2020-07-21 Novartis Ag Immunologically useful arginine salts
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
WO2014014207A1 (en) * 2012-07-20 2014-01-23 University-Industry Cooperation Group Of Kyung Hee University Antibody for epitope tagging, hybridoma cell line and uses thereof
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
EP2909334B1 (en) * 2012-10-17 2020-06-24 Enterome Gene signatures of inflammatory disorders that relate to the liver and to crohn's disease
US10288610B2 (en) * 2012-11-13 2019-05-14 The General Hospital Corporation Vitro assays for detecting Salmonella enterica serotype typhi
WO2014102694A1 (en) 2012-12-24 2014-07-03 Novartis Ag Novel mucinase for use in therapy or prophylaxis
AU2014224205C1 (en) 2013-03-08 2019-04-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP2971041B1 (en) 2013-03-15 2018-11-28 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
KR101525663B1 (ko) * 2013-05-10 2015-06-04 씨제이제일제당 (주) 신규 ｏ-포스포세린 배출 단백질 및 이를 이용한 ｏ-포스포세린의 생산방법
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
KR20150018227A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 외인성 푸마라아제 유전자를 포함하는 코리네박테리움 및 이를 이용한 c4 디카르복실산의 생산 방법
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
KR102523466B1 (ko) 2013-11-07 2023-04-20 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015095340A1 (en) 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
WO2015134808A2 (en) * 2014-03-06 2015-09-11 Research Institute At Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) * 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
ES2949172T3 (es) 2014-07-16 2023-09-26 Novartis Ag Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
ES2811337T3 (es) * 2015-04-07 2021-03-11 Metabolic Explorer Sa Microorganismo modificado para la producción optimizada de 2,4-dihidroxibutirato con eflujo de 2,4- dihidroxibutirato aumentado
US20160317615A1 (en) * 2015-05-01 2016-11-03 Jose Javier Lopez GONZALEZ T cell modulator
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11209972B2 (en) 2015-09-02 2021-12-28 D&M Holdings, Inc. Combined tablet screen drag-and-drop interface
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
JP7016521B2 (ja) * 2015-11-16 2022-02-07 国立大学法人 熊本大学 細胞の再プログラミングを誘導する組成物、及び該組成物を用いた多能性細胞の製造方法
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
CA3011901A1 (en) 2016-01-21 2017-07-27 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of bacteria
EP3701964B1 (en) * 2016-02-17 2023-11-08 Pepticom Ltd Peptide agonists and antagonists of tlr4 activation
WO2017160779A2 (en) * 2016-03-14 2017-09-21 The Translational Genomics Research Institute Methods and kits to identify klebsiella strains
WO2017158135A1 (en) * 2016-03-16 2017-09-21 Dsm Ip Assets B.V. Microbial production of nicotinic acid riboside
JP6818871B2 (ja) * 2016-04-27 2021-01-20 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
AU2018260733B2 (en) 2017-04-28 2023-08-17 Bioverde Tech Llc Methods and microorganisms for the fermentation of methane to multi-carbon compounds
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
KR20210031933A (ko) 2018-07-09 2021-03-23 코덱시스, 인코포레이티드 조작된 포스포펜토뮤타제 변이체 효소
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health
JP7541513B2 (ja) * 2018-10-05 2024-08-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
SG11202103001PA (en) 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
KR101991207B1 (ko) 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101991206B1 (ko) * 2018-11-29 2019-06-19 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
KR101996767B1 (ko) * 2018-11-29 2019-07-04 씨제이제일제당 (주) cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
BR112021011044A2 (pt) * 2018-12-10 2021-08-31 Flagship Pioneering Innovations Vi, Llc Sistemas ativos dinâmicos acromossômicos
EP3984546A4 (en) * 2019-05-15 2023-09-27 Universidad de Granada GENE THERAPY WITH THE HOKD AND LDRB GENES FOR CANCER TREATMENTS
CA3142272A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
CA3139124C (en) * 2019-06-21 2023-01-31 Inscripta, Inc. Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli
CN110441284B (zh) * 2019-07-23 2022-02-15 海南大学 一种可用于痕量检测的表面增强拉曼散射芯片的制备方法及所得产品和应用
KR102183209B1 (ko) * 2019-09-09 2020-11-26 씨제이제일제당 주식회사 L-쓰레오닌 배출 단백질의 변이체 및 이를 이용한 l-쓰레오닌 생산 방법
EP4053287A4 (en) * 2019-10-28 2023-11-01 Ajinomoto Co., Inc. Benzaldehyde production method
WO2021122528A1 (en) * 2019-12-20 2021-06-24 Basf Se Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
US20230105474A1 (en) * 2020-02-25 2023-04-06 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
CN111778224B (zh) * 2020-07-20 2021-06-01 成都薇合生物科技有限公司 尿酸酶或其同源酶及其应用
US11767519B2 (en) 2020-08-28 2023-09-26 Codexis, Inc. Engineered amylase variants
JP2023544783A (ja) * 2020-10-07 2023-10-25 コデクシス， インコーポレイテッド 操作されたホスホペントムターゼ改変体酵素
CN112391331B (zh) * 2020-11-12 2022-09-27 江南大学 一种过表达GatA基因的重组大肠杆菌及其应用
KR102792504B1 (ko) * 2020-12-28 2025-04-09 대상 주식회사 히스티딘에 의한 피드백 억제가 감소된 atp-prt 변이체 및 이를 발현하는 히스티딘 생산 균주
CN114137209B (zh) * 2021-02-01 2024-03-01 中国水产科学研究院黄海水产研究所 一种快速检测牡蛎疱疹病毒抗原的免疫荧光检测试纸条及应用
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
CN117222427A (zh) * 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
KR102707457B1 (ko) * 2021-06-11 2024-09-20 씨제이제일제당 주식회사 신규한 MdtH 변이체 및 이를 이용한 O-포스포세린, 시스테인 및 이의 유도체의 생산방법
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
US20250137050A1 (en) * 2021-08-18 2025-05-01 The Regents Of The University Of California Methods and compositions for determining risk of autism spectrum disorders
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
CN114107413B (zh) * 2021-11-03 2023-10-20 江苏香地化学有限公司 一种酶催化胞嘧啶生产胞苷的方法及应用
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023122632A1 (en) * 2021-12-21 2023-06-29 Sri International Dual targeting for cell-specific delivery to the central nervous system
CN114522230A (zh) * 2022-01-11 2022-05-24 上海市伤骨科研究所 一种蓝光和对苯醌联合杀菌方法
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN115286701A (zh) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用
US20240003886A1 (en) * 2022-06-15 2024-01-04 Quantum-Si Incorporated Directed protein evolution
WO2024073730A2 (en) * 2022-09-29 2024-04-04 The University Of Chicago Methods and systems for rna sequencing and analysis
AU2023362022A1 (en) 2022-10-19 2025-05-01 Glyprovac Aps Glycosylated yghj polypeptides from uropathogenic e. coli
CN118086235A (zh) * 2022-11-28 2024-05-28 宁波酶赛生物工程有限公司 一种合成d-泛解酸的酶催化剂和方法
KR20240120829A (ko) * 2023-01-31 2024-08-08 대상 주식회사 망가니즈 익스포터 신규 변이체 및 이를 이용한 l-히스티딘 생산 방법
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
WO2025017339A1 (en) * 2023-07-14 2025-01-23 Iowa State University Research Foundation, Inc. Escherichia coli nhaa membrane protein drug target and immunogenic compositions therefrom
CN116949027B (zh) * 2023-07-19 2024-12-24 浙江中医药大学 一种尿路致病性大肠埃希菌重组蛋白组合物ls、其构建、表达、纯化方法及其应用
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2025219177A1 (en) 2024-04-18 2025-10-23 Glyprovac Aps Optimized plasmids for expression of yghj polypeptides
CN118388664B (zh) * 2024-05-21 2024-12-03 广东省农业科学院动物卫生研究所 副猪嗜血杆菌融合抗原及其应用
CN119061031A (zh) * 2024-10-08 2024-12-03 安徽农业大学 一种水稻抗除草剂突变基因及其应用

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5334379A (en) 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
WO1992015582A1 (en) 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ES2149276T3 (es) 1993-07-15 2000-11-01 Minnesota Mining & Mfg Imidazo(4,5-c)piridin-4-aminas.
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU6489996A (en) 1995-07-14 1997-02-18 Somatogen, Inc. Methods for increasing protein expression
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP0942964A2 (en) 1996-11-22 1999-09-22 Human Genome Sciences, Inc. Thermostable polymerases having altered fidelity
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
DE69836977T2 (de) 1997-11-21 2007-10-18 Serono Genetics Institute S.A. Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
SG152917A1 (en) 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
EP1053015A2 (en) 1998-02-12 2000-11-22 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
EP2261350A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000009699A2 (en) 1998-08-14 2000-02-24 Chiron Corporation Method for producing yeast expressed hpv types 6 and 16 capsid proteins
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
MY125202A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
DE60039198D1 (de) 1999-03-26 2008-07-24 Vical Inc Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
EP1185691B1 (en) 1999-04-30 2009-04-29 Novartis Vaccines and Diagnostics, Inc. Neisseria genomic sequences and methods of their use
AU5561599A (en) 1999-05-05 2000-11-21 Sterrenbeld Biotechnologie North America, Inc. Dna promoter sequence for gene expression
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
HK1046861A1 (zh) 1999-09-24 2003-01-30 Smithkline Beecham Biologicals S.A. 包括聚氧乙烯烷基酯或者醚以及至少一種非離子表面活性劑的佐劑
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
AU2001277840A1 (en) 2000-03-07 2002-03-04 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1328641A2 (en) * 2000-03-10 2003-07-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1297005B1 (en) 2000-07-03 2009-08-26 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia pneumoniae
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
NZ524717A (en) 2000-09-11 2004-09-24 Chiron Corp Quinolinone derivatives
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
AU2002246592A1 (en) 2000-10-19 2002-08-06 Wisconsin Alumni Research Foundation Dna sequences of escherichia coli cft073
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7524509B2 (en) 2001-03-09 2009-04-28 Id Biomedical Corporation Of Quebec Proteosome-liposaccharide vaccine adjuvant
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
GEP20074099B (en) 2001-11-27 2007-05-10 Anadys Pharmaceuticals Inc 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030165870A1 (en) * 2002-03-01 2003-09-04 Blattner Frederick R. Novel sequences of E. coli CFT073
EP1342784A1 (en) * 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US7250443B2 (en) 2002-08-23 2007-07-31 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20040209370A1 (en) 2002-12-19 2004-10-21 Wonchul Suh Method for chromosomal engineering
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP1441036A1 (en) 2003-01-27 2004-07-28 Université de Nantes Method for the identification and isolation of strong bacterial promoters
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
JP4896715B2 (ja) 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
JP4049045B2 (ja) 2003-07-28 2008-02-20 トヨタ自動車株式会社 蓄熱装置付きエンジンシステム
KR101178776B1 (ko) * 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
RU2006134631A (ru) 2004-03-02 2008-04-10 Чирон Корпорейшн (Us) Иммуногенные композиции против chlamidia pneumoniae
DK1858920T3 (en) 2005-02-18 2016-02-29 Glaxosmithkline Biolog Sa PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI

Also Published As

Publication number Publication date
SG160329A1 (en) 2010-04-29
NZ597769A (en) 2013-09-27
ES2595363T3 (es) 2016-12-29
US9334313B2 (en) 2016-05-10
US20080193470A1 (en) 2008-08-14
EP2351772B1 (en) 2016-07-13
IL185359A0 (en) 2008-02-09
DK2351772T3 (en) 2016-09-05
US10035826B2 (en) 2018-07-31
US20160244489A1 (en) 2016-08-25
SI2351772T1 (sl) 2016-11-30
HUE027400T2 (en) 2016-10-28
CA2601924A1 (en) 2006-08-24
EP1858920A2 (en) 2007-11-28
NZ561042A (en) 2011-03-31
JP2008529558A (ja) 2008-08-07
SI1858920T1 (sl) 2016-07-29
CY1118149T1 (el) 2017-06-28
LT2351772T (lt) 2016-10-10
PL2351772T3 (pl) 2017-01-31
EP1858920B1 (en) 2016-02-03
HUE030881T2 (en) 2017-06-28
MX306302B (en) 2012-12-19
US20180298064A1 (en) 2018-10-18
DK1858920T3 (en) 2016-02-29
WO2006089264A2 (en) 2006-08-24
ES2569654T3 (es) 2016-05-12
AU2006214064A1 (en) 2006-08-24
JP2012152228A (ja) 2012-08-16
EP2351772A1 (en) 2011-08-03
WO2006089264A8 (en) 2008-03-06
PT2351772T (pt) 2016-09-22
WO2006089264A3 (en) 2007-04-05
CY1117732T1 (el) 2017-05-17
IL206012A0 (en) 2010-11-30
AU2006214064B2 (en) 2012-04-26
US20140356389A1 (en) 2014-12-04
NZ597685A (en) 2013-12-20
MX2007010043A (en) 2008-08-29
US8758764B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
MX306302B (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
IL185547A0 (en) Lipocalin protein
EP1856291A4 (en) NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
IL188611A (en) Type 1sp polypeptides are altered at the n-terminal end and used
EP1725661A4 (en) POLYNUCLEOTIDE FOR THE DETECTION OF SCHERICHIA COLI O157
GB0507537D0 (en) Protein resistant surfaces
IL193699A0 (en) Proteins, nucleic acids and medicaments
EP1904845A4 (en) IMPROVED RESULTS AND APPLICATION OF COMPARISON EXAMPLES OF PROTEIN EXPRESSIONS
SG131104A1 (en) Protein microarray slide
EP1666588A4 (en) NOVEL TRANSPORTED PROTEIN
IL173764A0 (en) Amino acids with affinity for the alpha2delta-protein
GB0514482D0 (en) Protein
HK1111175A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0724832D0 (en) Proteins and nucleic acids
EP1925670A4 (en) HIGH EXPRESSION ESCHERICHIA COLI VECTOR AND USES THEREOF
EP1759000A4 (en) POLYNUCLEOTIDES FOR DETECTION OF ESCHERICHIA COLI
GB0511861D0 (en) Proteins
GB0514481D0 (en) Proteins
GB0513505D0 (en) Proteins
GB0514788D0 (en) Proteins
GB0518460D0 (en) Protein assay
GB0515436D0 (en) Protein
GB0514718D0 (en) Protein
GB0512426D0 (en) Protein
GB0514717D0 (en) Protein